## Edgar Filing: ZUCCONI THEODORE DANIEL - Form 4

ZUCCONI T Form 4 April 18, 201	THEODORE DA	NIEL									
FORM	14									PPROVAL	
	Washington, D.C. 20549 is box ger 5. STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF 16. SECURITIES								OMB Number:	3735-0787	
if no long subject to Section 1 Form 4 o Form 5									Estimated a burden hou		
obligation may cont <i>See</i> Instru 1(b).	ns Section 17	Section 17(a) of the Public Utility Holding Company Act of 1935 or Section									
(Print or Type I	Responses)										
ZUCCONI THEODORE DANIEL Symbol GAI			2. Issuer Symbol	2. Issuer Name <b>and</b> Ticker or Trading ymbol				5. Relationship of Reporting Person(s) to Issuer			
			GALECTIN THERAPEUTICS INC [GALT]					(Check all applicable)			
INC., 4960	(First) ( CTIN THERAPI PEACHTREE AL BLVD., STE		3. Date of (Month/Da 04/16/20		ansaction			X Director Officer (give below)		9 Owner er (specify	
				ndment, Date Original th/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
NORCROS	S, GA 30071							Form filed by M Person	More than One Re	eporting	
(City)	(State)	(Zip)	Table	e I - Non-D	erivative S	Securi	ties Acc	quired, Disposed o	f, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date 2A. Deen (Month/Day/Year) Execution any (Month/E				4. Securities Acquired ion(A) or Disposed of (D) (Instr. 3, 4 and 5) (A)			Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
G				Code V	Amount	or (D)	Price	(Instr. 3 and 4)			
Common Stock	04/16/2018			М	4,000	А	\$ 0.89	5,083	D		
Common Stock	04/16/2018			S	4,000	D	\$ 3.58	1,083	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

### Edgar Filing: ZUCCONI THEODORE DANIEL - Form 4

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number onof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. H Der Sec (In:
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock option (right to buy)	\$ 0.89	04/16/2018		М	4,000	<u>(1)</u>	12/15/2026	Common stock	4,000	

# **Reporting Owners**

<b>Reporting Owner Name / Address</b>		Relationships							
	Director	10% Owner	Officer	Other					
ZUCCONI THEODORE DANIEL C/O GALECTIN THERAPEUTICS, INC. 4960 PEACHTREE INDUSTRIAL BLVD., ST NORCROSS, GA 30071	TE 240 X								
Signatures									
/s/ Jack W. Callicutt, by power of attorney	04/18/2018								
**Signature of Reporting Person	Date								
Explanation of Responses:									

## planation of Responses.

If the form is filed by more than one reporting person, see Instruction 4(b)(v). \*

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The options vested 100% on the date of Galectin Therapeutics, Inc.'s 2017 Annual Stockholders Meeting.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.